17:30
Saturday (22.10.2022)
08:45 - 10:15 Coffee Break
09:15 - 10:15 Opening Ceremony, Welcome Reception
10:15 - 12:15 Welcome and Introduction to the topic
- New trends in lymphoma therapy: future role of Hodgkin's lymphoma as a model for immuno-oncologic therapeutic approaches
- GÜRZENICH CONGRESS CENTER
- Marsiliussaal

12:15 - 13:45 Coffee Break
13:45 - 15:30 Welcome and introduction to the topic (K. Borchmann)
- Hodgkin's lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma (P. Ströck)
- The challenge of the older patient (P. Ströck)
- New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies (J. Zickefoose)
- Summary and farewell (P. Borchmann)

15:30 - 16:30 Coffee Break
16:30 - 18:00 Early Stages
- Standard treatment of early-stage HL (J. Ackford)
- Induction risk assessment of R-CHOP in HL (M. Happe)
- Workshop Report: NLPHL
- Workshop: Learning through International Collaboration
- Oral Abstract Presentations

18:00 - 19:30 Poster Session
19:00 - 20:30 Welcome Reception
20:30 - 22:30 Final Program

Sunday (23.10.2022)
07:30 - 09:00 Coffee Break
09:00 - 10:30 Living beyond Lymphoma
- Welcome and introduction
- Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcomes? (P. Borchmann)
- Checkpoint inhibition in HL: State of the art and future perspectives by MSD (P. Borchmann)
- The current role of PD-1 inhibition in the treatment of relapsed/refractory classical Hodgkin lymphoma (M. v. Trockow)
- Strategies to enhance checkpoint inhibition (P. Borchmann)
- Q&A

10:30 - 12:00 Oral Abstract Presentations
- Novel developments in R/R HL
- Novel approaches to lymphoma treatment by BeiGene
- Primary progressive HL
- AlloSCT in the era of anti-PD1 (A. Sureda)

12:00 - 13:30 Lunch
13:30 - 15:00 GZ2 - Bridging the gap between efficacy and toxicity in the treatment of stage III/IV Hodgkin lymphoma by Takeda (G. Collins, A. Herrera, P. L. Zinzani)
- Last off site talk: Trastuzumab Ezcetron (G. Echenique)
- Case Study #2 Female, early-30s
- Case Study #3 Male, mid-50s
- Case Study #3 Male, mid-50s

15:00 - 16:00 Coffee Break
16:00 - 17:30 Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory HL (A. Sureda)
- Welcome and Introduction (A. Sureda)
- Navigating complex treatment decisions in early relapse (A. Sureda)
- PET-guided eBEACOPP (E. Donges)
- Critical Case Study #3 (G. Echenique)

17:30 - 18:00 Coffee Break
18:00 - 19:30 Oral Immunotherapy (P. Armand, P. L. Zinzani)
- New findings and new challenges since last ISHL (P. Armand)
- Vision Corner
- The future of translational science in Hodgkin's disease (P. Armand)
- Best use of PD1 blockade in front-line (P. Dierickx)
- Leveraging PD1 blockade for cure (O. Baiocchi)
- Oral Abstract Presentations

19:00 - 20:30 Poster Session
19:00 - 20:30 Welcome Reception
20:30 - 22:30 Final Program
CONFERENCE COMMITTEE

Organizing Committee
Andreas Engert, MD, Symposium and GHSG Chairman
Sven Borchmann, MD, Symposium Secretary
Paul J. Bröckelmann, MD, Symposium Secretary
Dennis A. Eichenauer, MD, Symposium Secretary

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne
Kerpener Straße 62, D-50924 Cologne

Phone: +49 (0) 221 478-5933
Fax: +49 (0) 221 478-3778
Email: info@hodgkinsymposium.org
Further Information: www.hodgkinsymposium.org

Conference Management & Industrial Exhibition Secretariat
Gabriele Hanke
Travel & Congress Activities
Marienburger Str. 8; D-40883 Ratingen
Phone: +49 (0) 2102 669 36
Fax: +49 (0) 2102 9648 29
Email: info@tca-hanke.de

INTERNATIONAL SCIENTIFIC COMMITTEE
ACKNOWLEDGEMENTS

We wish to express our appreciation and gratitude to our partners.

ACADEMIC SPONSORS

Deutsche Forschungsgemeinschaft
Financial support was kindly provided by the Deutsche Forschungsgemeinschaft (DFG) within their program “International Scientific Events”.

KARL MUSSHOFF STIFTUNG
The Karl Musshoff Stiftung kindly supports the Karl Musshoff Prize in the categories “Best Clinical Abstract” and “Best Preclinical Abstract” as well as the “Poster Awards”.

B. BRAUN-STIFTUNG
DER GESUNDHEIT NEUE WEGE BEREITEN
Financial support was kindly provided by the B. Braun-Stiftung within their program “Scientific Events”.

ACADEMIC PARTNERS
EXHIBITION HALL

The scientific exhibition takes place at the Gürzenich Conference Center in the “Isabellensaal” on the first floor.

Opening hours of the Exhibition
Saturday, October 22, 2022  12:00-18:00
Sunday, October 23, 2022  08:00-18:00
Monday, October 24, 2022  08:00-18:00
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference and Scientific Committee</td>
<td>3</td>
</tr>
<tr>
<td>Sponsors</td>
<td>Acknowledgements</td>
</tr>
<tr>
<td>Exhibition</td>
<td>6-7</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>9</td>
</tr>
<tr>
<td>Welcome</td>
<td>11</td>
</tr>
<tr>
<td>General Information</td>
<td>12-15</td>
</tr>
<tr>
<td>Scientific Program</td>
<td></td>
</tr>
<tr>
<td><strong>Saturday 22.10.2022</strong></td>
<td>16-21</td>
</tr>
<tr>
<td>Workshops</td>
<td>Seminars</td>
</tr>
<tr>
<td><strong>Sunday 23.10.2022</strong></td>
<td>22-25</td>
</tr>
<tr>
<td>Scientific Program</td>
<td>Scientific Symposia</td>
</tr>
<tr>
<td><strong>Monday 24.10.2022</strong></td>
<td>26-28</td>
</tr>
<tr>
<td>Scientific Program</td>
<td>Scientific Symposia</td>
</tr>
<tr>
<td>Sponsoring</td>
<td>29</td>
</tr>
<tr>
<td>Oral and Poster Presentations</td>
<td></td>
</tr>
<tr>
<td>Advanced Stages</td>
<td>31-35</td>
</tr>
<tr>
<td>Early Stages</td>
<td>35-36</td>
</tr>
<tr>
<td>Genomics, Biology &amp; Microenvironment</td>
<td>36-42</td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>42-43</td>
</tr>
<tr>
<td>Living beyond Lymphoma</td>
<td>44-47</td>
</tr>
<tr>
<td>Older &amp; Frail Patients</td>
<td>47-48</td>
</tr>
<tr>
<td>Pediatric HL</td>
<td>48-49</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>49-50</td>
</tr>
<tr>
<td>Relapsed / Refractory</td>
<td>51-54</td>
</tr>
<tr>
<td>Speakers and Chairs</td>
<td>56-57</td>
</tr>
<tr>
<td>Award Winners ISHL12</td>
<td>58-59</td>
</tr>
</tbody>
</table>
Dear Colleagues and Friends,

We warmly welcome you to our 12th International Symposium on Hodgkin Lymphoma (ISHL12), hosted by the German Hodgkin Study Group (GHSG). This Symposium has become the central forum for clinicians and scientists involved in Hodgkin Lymphoma research and therapy, enabling in-depth exchange of the latest results and new ideas. Discussing the relevance of new findings for daily clinical practice in Hodgkin Lymphoma is one of the major goals of this Symposium. It will once more be held at the Gürzenich Conference Center in Cologne, which provides a wonderful communicative environment for discussion and networking.

ISHL12 will cover the most recent results in basic research, diagnostics and treatment of Hodgkin Lymphoma. A major focus will be on older and frail patients as well as early stage patients. A session on emerging cellular therapies will provide an in-depth insight at promising treatment options. Scientific symposia and workshops will complement the program. The Karl Musshoff Prize in the categories "Best Clinical Abstract" and "Best Preclinical Abstract" will be presented during the opening ceremony. On top of that, five Poster Awards have been selected by an international committee, based on the evaluation of their abstracts.

We thank all our contributors and cordially welcome you to ISHL12!

Andreas Engert
Symposium Chairman

Sven Borchmann
Paul J. Bröckelmann
Dennis A. Eichenauer
Symposium Secretary
Symposium Secretary
Symposium Secretary
Cloakroom
The cloakroom is located in the basement.

Conference Language
The conference language is English.

Continuing Medical Education
The 12th International Symposium on Hodgkin Lymphoma is certified by the European Board for Accreditation in Hematology (formerly EHA) with 35 EBAH credit points.
Please collect your certificates before departure at the registration desk (in the entrance hall of the Gürzenich).

Insurance
The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet
There will be free wifi at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.

Prayer Room
A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.

Conference Secretariat
Gürzenich Cologne | Martinstraße 29-37 | 50667 Cologne

During the conference, you can contact the Secretariat at
Phone: +49 (0) 173 939 07 30
Email: info@tca-hanke.de

Opening Hours of the Conference Secretariat
Saturday, October 22, 2022 07:00-18:00
Sunday, October 23, 2022 07:00-19:00
Monday, October 24, 2022 07:00-18:00

Accommodation
For accommodation support, please contact the conference management:
Phone: +49 (0) 2102 669 36
Email: info@tca-hanke.de

Name Badge
Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replacement fee.

Catering
During the breaks, complimentary coffee, fruit and refreshments will be available.
Registration
Pre-registration will close on October 21, 2022. All registrations received on or after October 22 will be considered as on-site registrations and will be charged the on-site fee.
Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on Saturday (October 22) and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia.
No refunds will be given.

Speakers Ready Room
The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Windows PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.

Non-Smoking
Please note that there will be a strict non-smoking policy at all conference facilities.

Transportation
The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15km) and Düsseldorf Airport (DUS; 45km).
From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes.
Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at “Gürzenichstraße”. The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public transport system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground “Heumarkt” (about 3 minutes walking distance from the Gürzenich).
If you want to take a taxi, you can either get in directly at one of the numerous taxi stands or you can order a taxi by phone from one of the taxi call centers (+49 221 170000 or +49 221 2882). Uber and Lyft or other ride sharing services do not operate reliably in Cologne or are not available at all. A taxi will most of the time be the better option.

Welcome Reception
On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.
Saturday, 22.10.2022

**Workshop 1 (parallel sessions)**  08:45-10:15

**Living beyond Lymphoma**  ROOM: GROSSER SAAL
Flora van Leeuwen (Amsterdam, NL), Lena Specht (Kopenhagen, DK)

08:45-09:15  Patient perspective  
Louise Jennings (Manchester, UK), Jack Richardson (Manchester, UK)

09:15-09:35  Organisation of HL survivorship care in the UK, ADAPT program  
John Radford (Manchester, UK)

09:35-09:55  Organisation of HL survivorship care in the Netherlands and design of INSIGHT cost-effectiveness study  
Berthe Aleman (Amsterdam, NL)

09:55-10:15  Organisation of HL survivorship care in the U.S.  
Kevin Oeffinger (Durham, US)

**Joint EHA–ISHL Symposium**  ROOM: RATSSTUBE
Peter Borchmann (Cologne, DE), Martin Dreyling (München, DE)

08:45-09:00  Introduction to GHSG  
Peter Borchmann (Cologne, DE)

09:00-09:15  In memoriam of Ton Hagenbeek  
Marie José Kersten (Amsterdam, NL)

09:15-09:45  Future perspectives for prognostication and MRD in chL  
Sven Borchmann (Cologne, DE)

09:45-10:15  EV miRNA in chL  
Michiel Pegtel (Amsterdam, NL)

**Workshop 2 (parallel sessions)**  08:45-10:15

**PET beyond Deauville**  ROOM: WEINKELLER
Sally Barrington (London, UK), Martin Hutchings (Copenhagen, DK), Carsten Kobe (Cologne, DE)

08:45-09:15  MTV and Baseline PET biomarkers  
Sally Barrington (London, UK)

09:15-09:45  Latest developments in software and PET technology  
Irene Buvat (Orsay, FR) shared talk with Carsten Kobe (Cologne, DE)

09:45-10:15  Imaging response in the context of immunotherapy  
Philippe Armand (Boston, US) shared talk with Martin Hutchings (Copenhagen, DK)
### Workshop 3 (parallel sessions) 08:45-10:15

**Innovation for Older Patients**  
**ROOM: MARSILIUSAAL**  
Paul Bröckelmann (Cologne, DE), Alexander Fosså (Oslo, NO)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45–09:05</td>
<td>Lymphoma Biology and Immunosenescence in Older Patients</td>
<td>Alessandra Tucci (Brescia, IT)</td>
</tr>
<tr>
<td>09:05–09:25</td>
<td>Efficacy and Safety of Targeted Drugs in Older HL Patients</td>
<td>Ingrid Glimelius (Stockholm, SE)</td>
</tr>
<tr>
<td>09:25–09:45</td>
<td>Current and Future Trial Landscape in Older Patients</td>
<td>Alexander Fosså (Oslo, NO)</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>Open Discussion Forum: Addressing Unmet Needs</td>
<td></td>
</tr>
</tbody>
</table>

### Seminar 2 (parallel sessions) 10:30-12:00

**Radiotherapy: Identifying the Beneficiaries**  
**ROOM: GROSSER SAAL**  
Christian Baues (Cologne, DE), Joachim Yahalom (New York, US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–11:00</td>
<td>Indications and current policy for radiotherapy in early and advanced stage HL based on GHSG randomized studies</td>
<td>Christian Baues (Cologne, DE)</td>
</tr>
<tr>
<td>11:00–11:30</td>
<td>Who benefits from adding radiotherapy even if PET-negative based on the RAPID study data</td>
<td>David Cutter (Oxford, UK)</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td>The experience of incorporating RT into CAR-T cell salvage programs- Does it apply to HL patients?</td>
<td>Brandon Imber (New York, US)</td>
</tr>
</tbody>
</table>

### Seminar 3 (parallel sessions) 10:30-12:00

**Learning from Pediatric HL**  
**ROOM: MARSILIUSAAL**  
Jonathan W. Friedberg (Rochester, US), Christine Mauz-Körholz (Gießen, DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:43</td>
<td>Framing the discussion and key issues in adolescent and young adult Hodgkin Lymphoma</td>
<td>Christine Mauz-Körholz (Gießen, DE)</td>
</tr>
<tr>
<td>10:56–11:13</td>
<td>SEARCH for CAYAHL Initiative</td>
<td>Jamie Flerlage (Memphis, US)</td>
</tr>
<tr>
<td>11:13–11:30</td>
<td>Importance of QoL and PROs in long-term follow-up of HL</td>
<td>Susan Parsons (Boston, US)</td>
</tr>
<tr>
<td>11:43–12:00</td>
<td>Lessons from European Network for Pediatric Hodgkin Lymphoma</td>
<td>Dieter Korholz (Gießen, DE)</td>
</tr>
</tbody>
</table>

### Workshop 4 (parallel sessions) 10:30-12:00

**Bringing Liquid Biopsy to Patients**  
**ROOM: KLEINER SAAL**  
Sven Borchmann (Cologne, DE), Davide Rossi (Bellinzona, CH)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:46</td>
<td>Liquid Biopsy in Lymphoma: The Swiss Experience</td>
<td>Cristina Pirosa (Bellinzona, CH)</td>
</tr>
<tr>
<td>10:46–11:02</td>
<td>Liquid Biopsy in Lymphoma: The Cologne experience</td>
<td>Michel Heger (Cologne, DE)</td>
</tr>
<tr>
<td>11:02–11:18</td>
<td>Integrating Fragmentomics and MRD in Lymphoma</td>
<td>Leo Meriranta (Helsinki, FL)</td>
</tr>
<tr>
<td>11:18–11:26</td>
<td>Challenges in bringing Liquid Biopsy to Lymphoma patients - Kick-off talk for round table</td>
<td>Sven Borchmann (Cologne, DE)</td>
</tr>
<tr>
<td>11:26–12:00</td>
<td>Challenges in bringing Liquid Biopsy to Lymphoma patients - Round table</td>
<td>All + Sally Barrington (London, UK), Bastian von Tresckow (Cologne, DE)</td>
</tr>
</tbody>
</table>

### Workshop 5 (parallel sessions) 10:30-12:00

**NLPHL**  
**ROOM: WEINKELLER**  
Michael S. Binkley (Stanford, US), Dennis Eichenauer (Cologne, DE), Sylvia Hartmann (Frankfurt, DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–11:00</td>
<td>Where belongs NLPHL? Biology and pathology</td>
<td>Sylvia Hartmann (Frankfurt, DE)</td>
</tr>
<tr>
<td>11:00–11:30</td>
<td>Treatment of NLPHL: what evidence is available?</td>
<td>Dennis Eichenauer (Cologne, DE)</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td>The GLOW database: a tool to answer open questions in NLPHL</td>
<td>Michael S. Binkley (Stanford, US)</td>
</tr>
</tbody>
</table>

### Workshop 6 (parallel sessions) 10:30-12:00

**Learning through International Collaboration**  
**ROOM: RATSSTUBE**  
Peter Borchmann (Cologne, DE), Alison J. Moskowitz (New York, US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:43</td>
<td>Framing the discussion and key issues in adolescent and young adult Hodgkin Lymphoma</td>
<td>Christine Mauz-Körholz (Gießen, DE)</td>
</tr>
<tr>
<td>10:56–11:13</td>
<td>SEARCH for CAYAHL Initiative</td>
<td>Jamie Flerlage (Memphis, US)</td>
</tr>
<tr>
<td>11:13–11:30</td>
<td>Importance of QoL and PROs in long-term follow-up of HL</td>
<td>Susan Parsons (Boston, US)</td>
</tr>
<tr>
<td>11:43–12:00</td>
<td>Lessons from European Network for Pediatric Hodgkin Lymphoma</td>
<td>Dieter Korholz (Gießen, DE)</td>
</tr>
</tbody>
</table>
Scientific Symposium 12:15-13:45  
(BeiGene)  

Opening paths to the next chapters of lymphoma treatment  
Peter Borchmann (Cologne, DE)  
ROOM: GROSSER SAAL

12:15-12:20  
Welcome and Introduction to the topic  
Peter Borchmann (Cologne, DE)

12:20-12:45  
Hodgkin’s lymphoma as a model for immunologic therapeutic approaches to lymphoma  
Paul Bröckelmann (Cologne, DE)

12:45-13:10  
The challenge of the older patient in lymphoma therapy  
Graham Collins (Oxford, UK)

13:10-13:40  
New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies  
Pier Luigi Zinzani (Bologna, IT)

13:40-13:45  
Summary and farewell  
Peter Borchmann (Cologne, DE)

Scientific Session 1 14:00-15:30  

Early Stages  ROOM: GROSSER SAAL  
Marc André (Yvoir, BE), Hans-T. Eich (Münster, DE)

14:00-14:22  
Standard treatment of early-stage HL  
John Radford (Manchester, UK)

14:22-14:45  
Individual risk assessment of RT in HL  
Richard Hoppe (Stanford, US)

14:45-14:51  
Workshop Report: NLPHL, Michael S. Binkley (Stanford, US), Dennis Eichenauer (Cologne, DE), Sylvia Hartmann (Frankfurt, DE)

14:51-15:04 | T020  
Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin Lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies  

15:04-15:17 | T021  
Radiation-Free Therapy as the Initial treatment of Good-prognosis early non-bulky Hodgkin Lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial  

15:17-15:30 | T022  
Sharing decisions regarding radiotherapy for Hodgkin Lymphoma: a qualitative study of the experiences of patients and clinicians in the UK  

Scientific Symposium 16:00-17:30  
(BMS)

CAR T cell therapy in B Cell NHL: status quo and future perspectives  ROOM: GROSSER SAAL  
Paula Cramer (Cologne, DE), Christoph Scheid (Cologne, DE)

16:00-16:30  
Status quo of CAR T cell therapy for r/r DLBCL  
Peter Borchmann (Cologne, DE)

16:30-17:00  
New perspective for the treatment of r/r CLL  
Paula Cramer (Cologne, DE)

17:00-17:30  
CAR T - Lessons Learned  
Christoph Scheid (Cologne, DE)

OPENING CEREMONY

Gürzenich Conference Center  ROOM: GROSSER SAAL  18:00

18:00-18:05  
Welcoming Address  
Andreas Engert (Cologne, DE)

18:05-18:20  
Award Ceremony  
Karl-Musshoff Awards & Poster Awards, Peter Borchmann, Sven Borchmann, Paul Bröckelmann, Dennis Eichenauer

18:20-18:30  
Introduction to the Keynote Lecturer  
Volker Diehl (Cologne, DE)

18:30-19:00  
Keynote Lecture  
Ugur Şahin (Mainz, DE)

Followed by Welcome Reception

Poster Session  GÜRZENICH, FOYER  19:00-20:30

Please join the poster presentation and take the chance to discuss the results with your colleagues.
Sunday, 23.10.2022

**Scientific Session 2** 07:30-09:00

**Interactive Case Discussions**  **ROOM: GROSSER SAAL**

**Faculty:** Tim Illidge (Manchester, UK), Josee Zijlstra (Amsterdam, NL)

Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion

1. Greyzone Lymphoma (László Pinczés, Debrecen, HU)
2. Anti-PD1 Failure (Graham Collins, Oxford, UK)
3. COVID19 Immunity in Lymphoma (Sybille Mellinghoff, Cologne, DE)
4. Primary progressive HL (Anne Sophie Jacob, Cologne, DE)

**Scientific Session 3** 09:15-10:15

**Emerging Cellular Therapies - a Role in HL?**  **ROOM: GROSSER SAAL**

Steve Ansell (Rochester, US), Peter Borchmann (Cologne, DE)

**09:15-09:35**
Emerging indications for cellular therapy  Peter Borchmann (Cologne, DE)

**09:35-09:55**
tbd

**09:55-10:15**
Cellular therapy in HL  Barbara Savoldo (Chapel Hill, US)

**Scientific Session 4** 10:30-12:00

**Living beyond Lymphoma**  **ROOM: GROSSER SAAL**

Flora van Leeuwen (Amsterdam, NL), John Radford (Manchester, UK)

**10:30-10:53**
Emerging indications for cellular therapy  Peter Borchmann (Cologne, DE)

**10:53-11:16**
GHSG data on fertility, fatigue and social reintegration and the ongoing EMBRACE study  Karolin Behringer (Cologne, DE)

**11:16-11:21**
Workshop Report: Living beyond Lymphoma, Flora van Leeuwen (Amsterdam, NL), Lena Specht (Kopenhagen, DK)

**11:21-11:34 | T064**

**11:34-11:47 | T065**

**11:47-12:00 | T066**
Scientific Symposium 12:15–13:15

**Checkpoint Inhibition in Hodgkin Lymphoma - State of the art and future perspectives**

**ROOM: GROSSER SAAL**

12:15–12:35
Firstline therapy of classical Hodgkin Lymphoma - How can immunotherapy improve outcome?  
Peter Borchmann (Cologne, DE)

12:35–12:55
The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma  
Bastian von Tresckow (Cologne, DE)

12:55–13:15
Strategies to enhance checkpoint inhibition  
Paul Bröckelmann (Cologne, DE)

Scientific Session 5 14:00–15:30

**Older and Frail Patients**

**ROOM: GROSSER SAAL**  
Raul Cordoba (Madrid, ES), Andrew Evens (New Brunswick, US)

14:00–14:23
Managing an Older Lymphoma Patient  
Raul Cordoba Mascuñano (Madrid, ES)

14:23–14:46
Treatment Strategies in Older HL Patients  
Andrew Evens (New Brunswick, US)

14:46–14:51
Workshop Report: Innovation for Older patients, Alexander Fosså (Oslo, NO), Paul Bröckelmann (Cologne, DE)

14:51–15:04 | T082
AVD - a possible golden standard in the first-line treatment of older classical Hodgkin Lymphoma patients  

15:04–15:17 | T083
The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma  

14:17–15:30 | T084
Treatment patterns and outcomes for Hodgkin’s Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s Lymphoma Registry  

Scientific Symposium 16:00–17:30

**Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma**

**ROOM: GROSSER SAAL**

16:00–16:05
Welcome and Introduction  
Anna Sureda (Barcelona, ES)

16:05–16:25
Navigating Complex Treatment Decisions in R/R HL  
Theodoros Vassiliakopoulos (Athens, GR)

16:25–16:40
Challenging Case Study #1  
Martin Hutchings (Copenhagen, DK)

16:40–17:00
Learning from Real-World Evidence to Inform Treatment Decisions in R/R HL  
Anna Sureda (Barcelona, ES)

17:00–17:30
Challenging Case Study #2  
Martin Hutchings (Copenhagen, DK)

Scientific Session 6 18:00–19:30

**Immunotherapy**

**ROOM: GROSSER SAAL**

Philippe Armand (Boston, US), Pier Luigi Zinzani (Bologna, IT)

18:00–18:20
New findings and new challenges since last ISHL  
Steve Ansell (Rochester, US)

18:20–18:45
Vision Corner  
The future of translational science in Hodgkin  
Margaret Shipp (Boston, US)

18:45–19:00
Vision Corner  
The best use of PD1 blockade in front-line  
Paul Bröckelmann (Cologne, DE)

19:00–19:15
Vision Corner  
Leveraging PD1 blockade for cure  
Graham Collins (Oxford, UK)

19:15–19:17 | T057
Circulating tumor DNA in classical Hodgkin Lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume  

19:17–19:30 | T058
Safety and Dose-Expansion Study of Combination Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment  
### Scientific Session 7  07:30-09:00

**Advanced Stages**  **ROOM: GROSSER SAAL**

Olivier Casasnovas (Dijon, FR), John Radford (Manchester, UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-07:35</td>
<td>Why I recommend BV-AVD</td>
<td>Ranjana Advani (Stanford, US)</td>
</tr>
<tr>
<td>07:35-07:40</td>
<td>Why I recommend PET-guided ABVD</td>
<td>Peter Johnson (Southampton, UK)</td>
</tr>
<tr>
<td>07:40-07:45</td>
<td>Why I recommend PET-guided eBEACOPP</td>
<td>Peter Borchmann (Cologne, DE)</td>
</tr>
<tr>
<td>07:45-08:30</td>
<td>Discussion forum</td>
<td>Patient: J. Richardson (Manchester, UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nurse: S. Wells (Manchester, UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Physician: M. Dreyling (München, DE)</td>
</tr>
<tr>
<td>08:30-08:35</td>
<td>Workshop Report: Learning through International Collaboration</td>
<td>Peter Borchmann (Cologne, DE), Alison, J. Moskowitz (New York, US)</td>
</tr>
</tbody>
</table>

### Scientific Session 8  09:15-10:15

**Special Situations in HL**  **ROOM: GROSSER SAAL**

Richard Hoppe (Stanford, US), Marie José Kersten (Amsterdam, NL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15-09:35</td>
<td>HL in Pregnancy</td>
<td>Daan Dierickx (Leuven, BE)</td>
</tr>
<tr>
<td>09:35-09:55</td>
<td>HIV-positive HL</td>
<td>Otavio Baiocchi (São Paulo, BR)</td>
</tr>
<tr>
<td>09:55-10:15</td>
<td>alloSCT in the era of anti-PD1</td>
<td>Anna Sureda (Barcelona, ES)</td>
</tr>
</tbody>
</table>

### Scientific Session 9  10:30-12:00

**Genomics, Biology & Microenvironment**  **ROOM: GROSSER SAAL**

Wolfram Klapper (Kiel, DE), Ralf Küppers (Essen, DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:53</td>
<td>Biological Classification of HL by Liquid Biopsy</td>
<td>Sven Borchmann (Cologne, DE)</td>
</tr>
<tr>
<td>10:53-11:16</td>
<td>Single Cell Transcriptomics of HL</td>
<td>Christian Steidl (Vancouver, CA)</td>
</tr>
<tr>
<td>11:16-11:21</td>
<td>Workshop Report: Bringing Liquid Biopsy to Patients</td>
<td>Sven Borchmann (Cologne, DE), Davide Rossi (Bellinzona, CH)</td>
</tr>
<tr>
<td>11:34-12:00</td>
<td>High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin Lymphoma diagnosis by several years</td>
<td>Diepstra A, Nolte I M, Van Den Berg A, Levin I L, Martinez-Maza O</td>
</tr>
</tbody>
</table>

### Scientific Symposium 12:15–13:45

**(Takeda)**

**Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma**  **ROOM: GROSSER SAAL**

Graham Collins (Oxford, UK), Alex Herrera (Duarte, US), Pier Luigi Zinzani (Bologna, IT)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details to be confirmed</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15-13:15</td>
<td>Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1</td>
<td></td>
</tr>
<tr>
<td>13:15-13:45</td>
<td>Bridging the gap: Balancing efficacy and toxicity in three challenging case studies, A debate and audience discussion with our panel</td>
<td></td>
</tr>
<tr>
<td>13:45-13:45</td>
<td>Audience Q&amp;A</td>
<td>Details to be confirmed</td>
</tr>
<tr>
<td>13:45-13:45</td>
<td>Summary and close</td>
<td>Details to be confirmed</td>
</tr>
</tbody>
</table>
Scientific Session 10  
**14:00-15:30**

**Relapsed / Refractory HL**  
**ROOM: GROSSER SAAL**

Ranjana Advani (Stanford, US), Craig H. Moskowitz (Miami, US)

14:00-14:23

1st Relapse of HL  
Craig H. Moskowitz (Miami, US)

14:23-14:46

Novel developments in R / R HL  
Graham Collins (Oxford, UK)

14:46-14:51

Workshop Report: PET beyond Deauville. Sally Barrington (London, UK), Martin Hutchings (Copenhagen, DK), Carsten Kobe (Cologne, DE)

14:51-15:04 | T098

Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial  

15:04-15:17 | T099

High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin Lymphoma  

15:17-15:30 | T100

Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the EOCG-ACRIN Research Group [E4412: Arms A-I]  

Closing Remarks  
**ROOM: GROSSER SAAL**  
**15:30-16:00**

Conference Highlights  
Ranjana Advani (Stanford, US)

Farewell  
**16:00-16:30**

We would very much like to thank all of our partners for their generous sponsoring.

<table>
<thead>
<tr>
<th>Name of Sponsor</th>
<th>Total Sponsoring Amount</th>
<th>Sponsoring Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>acromion GmbH</td>
<td>€ 500,00</td>
<td>Flyer distribution</td>
</tr>
<tr>
<td>AstraZeneca GmbH</td>
<td>€ 1.000,00</td>
<td>Flyer distribution, Logo</td>
</tr>
<tr>
<td>Beigene Switzerland GmbH</td>
<td>€ 49.600,00</td>
<td>Symposia, Booth</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>€ 52.000,00</td>
<td>Symposia</td>
</tr>
<tr>
<td>Chugai Pharma Deutschland GmbH</td>
<td>€ 2.200,00</td>
<td>Booth</td>
</tr>
<tr>
<td>Janssen-Cilag GmbH</td>
<td>€ 4.400,00</td>
<td>Booth</td>
</tr>
<tr>
<td>MSD SHARP &amp; DOHME GMB</td>
<td>€ 39.000,00</td>
<td>Symposia, Booth</td>
</tr>
<tr>
<td>Roche Pharma AG</td>
<td>€ 4.400,00</td>
<td>Booth</td>
</tr>
<tr>
<td>Takeda Pharmaceuticals U.S.A., Inc.</td>
<td>€ 111.500,00</td>
<td>2 Symposia, Booth, Email Campaign</td>
</tr>
<tr>
<td>Tessa Therapeutics Ltd</td>
<td>€ 5.000,00</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
ABSTRACTS
ORAL AND POSTER PRESENTATIONS

Posters will be presented during the Poster Session and Welcome Reception (Saturday, October 23, 19:00 to 20:30).

All poster presenters are kindly requested to be presented at their poster boards during that time.

Advanced Stages

Talks

Q T001
FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin Lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Q T002
Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

Posters

P003
A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s Lymphoma registered in the Lymphoma clinic at Tata Memorial Centre
Jain H, Singh A, Sengar M, Eipe T, Mehta H, Bagal B, Thorat J, Nayak L, Sharma N
P004
Advanced stage classical Hodgkin Lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials

P005
Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin Lymphoma, even the PET-adapted era. A single center retrospective study

P006
Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-Lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione Italiana linfomi

P007
Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
Dorokhina E, Moiseeva T, Kovrigina A, Shuplestova I, Al-Radi L, Chabaeva Y A, Mangasarova Y

P008
Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin Lymphoma

P009
Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

P010
Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium

P011
IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose

P012
Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience

P013
Outcomes of first-line treatment (FL) of classical Hodgkin Lymphoma (cHL) in Argentina: a real life multicenter retrospective study
**P014**
Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin Lymphoma patients

**P015**
Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

**P016**
Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)

**P017**
The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin Lymphoma

**P018**
Treatment outcomes in classical Hodgkin Lymphoma (HL): 5-year update report from the Brazilian Prospective Registry

**P019**
Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
Dorokhina E, Moiseeva T, Kovrigina A, Shupletsova I, Al-Radi L, Chabaeva Y A, Mangasarova Y

**Early Stages**

**Talks**

**T020**
Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin Lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

**T021**
Radiation-Free Therapy as the Initial treatment of Good-prognosis early non-bulky Hodgkin Lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial

**T022**
Sharing decisions regarding radiotherapy for Hodgkin Lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
**P023**
PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin Lymphoma

**P024**
Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma - Data from the Prospective, Multi-center Phase III HD16 Trial

**P025**
RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin Lymphoma

**P026**
Characterization of cancer-associated fibroblasts in classical Hodgkin Lymphoma

**P027**
High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin Lymphoma diagnosis by several years
Diepstra A, Nolte I M, Van Den Berg A, Levin L I, Martínez-Maza O

**P028**
Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin Lymphoma treated with PD-1 blockade

**P029**
Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?

**P030**
Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study

**P031**
CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
P032
Circulating immune biomarkers in classical Hodgkin Lymphoma in relation to tumor burden and response to treatment

P033
Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin Lymphoma
Shupletsova I, Kovrigina A, Dorokhina E, Moiseeva T

P034
Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment

P035
CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin Lymphoma
Kilian A L, Lollies A, Weniger M A, Küppers R

P036
Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin Lymphoma
Grohmann J, Kredatusova A, Navratilova J, Hanackova V, Urbankova H, Prochazka V, Papajik T

P037
High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin Lymphoma

P038
HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin Lymphoma

P039
HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin Lymphoma

P040
LINE-1 reverse transcriptase activity in Hodgkin Lymphoma cells
Wadel A, Jaster L, Staege M S

P041
Low percentage of T lymphocytes in Hodgkin’s Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status

P042
Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma

P043
Molecular pathogenesis of Hodgkin Lymphoma
P044
PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma

P045
Plasma proteome profiling of cardiotoxicity in patients with Hodgkin Lymphoma

P046
Preclinical evaluation of novel repurposed drug combinations in Hodgkin Lymphoma

P047
Predictive role of the Hodgkin Lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group

P048
Predictors of risk of relapse in classic Hodgkin Lymphoma by flow cytometry
Fromm J, Tang C, Naresh K N

P049
Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin Lymphoma

P050
Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells

P051
Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers

P052
Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)

P053
The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)

P054
The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma

P055
Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin Lymphoma
Buhtoliarov I, Hill B, Klirsch I, Richter N, Hanna R
Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells
Lein P, Anchang C G, Volkmer I, Staegge M S

Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma

Circulating tumor DNA in classical Hodgkin Lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Treatment

The efficacy and safety of nivolumab 40mg therapy versus 3mg/kg in patients with relapsed and refractory classic Hodgkin Lymphoma
Fedorova L, Lepik K, Mikhailova N, Kondakova E, Komarova Y, Kotselyabina P, Borzenkova E, Baykov V, Moiseev I, Kulagin A

Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
Bröckelmann P J, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A
Living beyond Lymphoma

Talks

T064
Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin Lymphoma survivors

T065
Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

T066
Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study

Posters

P067
A pilot of lung cancer screening for survivors of Hodgkin Lymphoma

P068
A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
Marková J, Mociková H, Gašarová L, Klásková K, Maco M, Dedecková K, Kozák T

P069
Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin Lymphoma patients
Chuzel C, Simon V, Béhal H, Morschhauser F, Decanter C, Nudel M

P070
Design of the INSIGHT study, evaluation of long-term follow-up care for Lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of Lymphoma treatment and associated costs?

P071
First results of cardiovascular screening in a survivorship care program for Hodgkin Lymphoma survivors in the Netherlands

P072
Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma
Bates C, Bamigbola F, Warwick L

P073
Increased risk of colorectal cancer following treatment for Hodgkin Lymphoma
**P074**

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - A Nationwide Danish Cohort Study

**P075**

My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients

**P076**

Pneumococcal infection in splenectomised Hodgkin Lymphoma patients: Do they pose a problem today and what is the best long-term strategy?
Björkholm M, Weibull C E, Dickman P

**P077**

Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin Lymphoma patients, using pre-chemotherapy PET-CT scans
Shakir R, Butterworth V, Ntentas G, Ramroth J, Cutter D

**P078**

Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
Stadtbaeumer N, Mayer A, Borchmann P

**P079**

PROCTCAE as a patient-reported outcome measurement (PROM) questionnaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians

**P080**

The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment

**P081**

Treatment-related circulatory diseases and mortality in Hodgkin Lymphoma patients using multi-state modelling and relative survival

**Older & Frail Patients**

**Talks**

**Q T082**

AVD - a possible golden standard in the first-line treatment of older classical Hodgkin Lymphoma patients

**Q T083**

The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
Treatment patterns and outcomes for Hodgkin’s Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s Lymphoma Registry

Epidemiology and results of the first line therapy of HIV-related Hodgkin Lymphoma: Russian retrospective multicenter study

Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma

Case series of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Tanzania. A common entity in East Africa?

Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study

Staging of Lung Lesions Survey Demonstrates Continued Need for Harmonization

Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin Lymphoma patients

Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
From involved-field to involved-node - Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group

Long-term outcomes of bulky classic Hodgkin Lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases


Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’s Lymphoma

The status quo of involved-field radiotherapy - Quality analysis of radiotherapy in the GHSG HD 16

Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial

High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin Lymphoma

Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
**P101**
Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s Lymphoma

**P102**
Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma

**P103**
Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.

**P104**
Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic

**P105**
Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles

**P106**
Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin Lymphoma is a feasible treatment option - a single center experience
Erenmalm A, Linderoth J

**P107**
Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data

**P108**
Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin Lymphoma

**P109**
One-Day Brentuximab-Bendamustine (120mg/m²) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin Lymphoma

**P110**
Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
P111
Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

P112
Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma

P113
Promising results with anti-PD-1 therapy in primary refractory Hodgkin Lymphoma: a single-centre report

P114
Very late relapses in patients with Hodgkin Lymphoma occurring >e;5 years after initial treatment with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
SPEAKERS AND CHAIRS

Advani, Ranjana: radvani@stanford.edu
Aleman, Berthe: b.aleman@nki.nl
André, Marc: marc.andre@uclouvain.be
Ansell, Stephen: ansell.stephen@mayo.edu
Armand, Philippe: Philippe_Armand@dfci.harvard.edu
Baiocchi, Otavio: obaiocchi@gmail.com
Barrington, Sally: sally.barrington@kcl.ac.uk
Baues, Christian: christian.baues@uk-koeln.de
Behringer, Karolin: karolin.behringer@uk-koeln.de
Binkley, Michael S.: msb996@stanford.edu
Björkholm, Magnus: magnus.bjorkholm@sll.se
Borchmann, Peter: Peter.Borchmann@uni-koeln.de
Borchmann, Sven: sven.borchmann@uk-koeln.de
Bröckelmann, Paul: paul.broeckelmann@uk-koeln.de
Buvat, Irene: irene.buvat@u-psud.fr
Casasnovas, Olivier: olivier.casasnovas@chu-dijon.fr
Collins, Graham: graham.collins@ouh.nhs.uk
Cordoba Mascuñano, Raul: raul.cordoba@fjd.es
Cutter, David: david.cutter@ndph.ox.ac.uk
Diehl, Volker: v.diehl@uni-koeln.de
Dierickx, Daan: daan.dierickx@uzleuven.be
Dreyling, Martin: Martin.Dreyling@med.uni-muenchen.de
Elch, Hans: hans.elch@ukmuenster.de
Eichener, Dennis: dennis.eichener@uk-koeln.de
Evens, Andrew: ae378@cinj.rutgers.edu
Flerlage, Jamie: jamie.flerlage@stjude.org
Fossa, Alexander: afl@ous-hf.no
Friedberg, Jonathan: jonathan_friedberg@urmc.rochester.edu
Glimelius, Ingrid: ingrid.glimelius@igp.uu.se
Hartmann, Sylvia: s.hartmann@em.uni-frankfurt.de
Heger, Michel: jan-michel.heger@uk-koeln.de
Hertzberg, Mark: mhertzberg10@gmail.com
Hoppe, Richard: Richard.Hoppe@stanford.edu
Howe, Tracy: tracy.howe4@nhs.net
Hutchings, Martin: martin.hutchings@gmail.com
Illdidge, Tim: Tim.Illdidge@ics.manchester.ac.uk
Imber, Brandon: imberb@mskcc.org
Jacob, Anne Sophie: anne.jacob@uk-koeln.de
Jennings, Louise: louisejenning24@hotmail.com
Kersten, Marie José: m.j.kersten@amsterdamumc.nl
Klapper, Wolfram: wklapper@path.uni-kiel.de
Kobe, Carsten: carsten.kobe@uk-koeln.de
Körholz, Dieter: dieter.koerholz@paediat.med.uni-giessen.de
Küppers, Ralf: ralf.kueppers@uk-essen.de
Linton, Kim: Kim.M.Linton@manchester.ac.uk
Mauz-Körholz, Christine: christine.mauz-koerholz@paediat.med.uni-giessen.de
Mellinghoff, Sybille: sibylle.mellinghoff@uk-koeln.de
Meriranta, Leo: leo.meriranta@helsinki.fi
Moskowitz, Alison: moskowia@mskcc.org
Moskowitz, Craig: CHM78@miami.edu
Oeffinger, Kevin: kevin.oeffinger@duke.edu
Parsons, Susan: sparsons@tuftsmedicalcenter.org
Pegtel, Michiel: d.pegtel@vumc.nl
Pinczés, László Imre: pinczes.laszlo.imre@med.unideb.hu
Pirosa, Cristina: Maria.Pirosa@eoc.ch
Radford, John: John.Radford@manchester.ac.uk
Richardson, Jack: jrojr92@googlemail.com
Rodig, Scott: srodig@bwh.harvard.edu
Rosenwald, Andreas: rosenwald@uni-wuerzburg.de
Rossi, Davide: Davide.Rossi@eoc.ch
Savoldo, Barbara: bsavoldo@med.unc.edu
Schaapveld, Michael: m.schaapveld@nki.nl
Shipp, Margaret: Margaret_shipp@dfci.harvard.edu
Specht, Lena: specht@rh.dk
Steidl, Christian: CSTeidl@bccancer.bc.ca
Sureda, Anna: annesureda@iconcologia.net
Tucci, Alessandra: alessandra.tucci@asst-spedalicivili.it
van Leeuwen, Flora: f.v.leeuwen@nki.nl
von Tresckow, Bastian: Bastian.vonTresckow@uk-essen.de
Wells, Sarah: s.wells7@nhs.net
Yahalom, Joachim: yahalomj@mskcc.org
Zijlstra, Jose: j.zijlstra@amsterdamumc.nl
Zinzani, Pierluigi: pierluigi.zinzani@unibo.it
KARL MUSSHOFF PRIZE
Best Clinical Abstract

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and contribution to the field of Hodgkin Lymphoma.

This year’s prize in the category “Best Clinical Abstract” will be awarded to:

ALISON MOSKOWITZ

KARL MUSSHOFF PRIZE
Best Preclinical Abstract

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and contribution to the field of Hodgkin Lymphoma.

This year’s prize in the category “Best Preclinical Abstract” will be awarded to:

JULIA PACZKOWSKA

POSTER AWARD

Lilian Beeck
Julia Driessen
David Jones
Laman Mammadova
Andrea Visentin
Further information will be available at
www.hodgkinsymposium.org